# Ligand Pharmaceuticals Inc: Form 8-K, filed Jun 25, 2026

- Company: [Ligand Pharmaceuticals Inc](/companies/lgnd.md) (CIK 886163)
- Form: 8-K
- Filed: 2026-06-25
- Accepted by EDGAR: Jun 25, 2026, 17:00 ET
- Period: 2026-06-25
- Accession: 0001193125-26-282990
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/886163/000119312526282990/d167360d8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/886163/000119312526282990/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 2.03: New direct financial obligation
- Item 3.02: Unregistered sale of equity
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/886163/000119312526282990/d167360d8k.htm

Filed Jun 25, 2026.
Source: SEC EDGAR, the filing index for accession 0001193125-26-282990. Last ingested by Listed: Oct 29, 2026, 07:16 ET. No prices; not investment advice.